On October 20, 2023, the board of directors of Quince Therapeutics, Inc. appointed Luca Benatti to serve as a director of the Company, effective as of the first business day following the closing of the EryDel Acquisition. Mr. Benatti was designated as a Class II director whose term expires at the Company?s 2024 Annual Meeting of Stockholders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7 USD | +7.69% | -1.41% | -33.33% |
Jun. 05 | Transcript : Quince Therapeutics, Inc. - Shareholder/Analyst Call | |
Jun. 03 | Quince Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EryDex System | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-33.33% | 30.25M | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- QNCX Stock
- News Quince Therapeutics, Inc.
- Quince Therapeutics, Inc. Appoints Luca Benatti as Director